Mesothelioma pp 301-322 | Cite as

Peritoneal Mesothelioma: Diagnosis and Management



Peritoneal mesothelioma (PM) is an uncommon and locally aggressive tumor encompassing a wide spectrum of biological behaviors, from clinically indolent to rapidly fatal disease. PM has been historically treated with debulking (DBK) surgery and/or palliative systemic chemotherapy (sCT), resulting in a median survival of only 1 year in the malignant variants. The biology of this disease has been poorly understood until recent years when mechanisms of resistance to therapy and new potential molecular therapeutic targets have been thoroughly investigated. Pathological and histological classifications of PM are still evolving. The clinical management of these conditions has improved during the last 30 years with the advent of a comprehensive treatment approach involving cytoreductive surgery (CRS) and intraperitoneal drug administration, such as hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in increased patient survival. This review addresses relevant clinical and biological issues of PM, including molecular features, diagnosis, pathology, role of modern systemic and targeted therapies, patient selection for combined surgical treatment, surgical technique, and prognostic factors.


Diffuse malignant peritoneal mesothelioma Cytoreductive surgery Hyperthemic intraperitoneal chemotherapy (HIPEC) Well differentiated papillary peritoneal mesothelioma Multicystic peritoneal mesothelioma 


  1. 1.
    Robinson BWS, Lake RA. Advanced in malignant mesothelioma. N Engl J Med. 2005;353:1591–603.PubMedCrossRefGoogle Scholar
  2. 2.
    Conti S, Minelli G, Ascoli V, Marinaccio A, Bonafede M, Manno V, Crialesi R, Straif K. Peritoneal mesothelioma in Italy: trends and geography of mortality and incidence. Am J Ind Med. 2015;58:1050–8.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.CrossRefGoogle Scholar
  5. 5.
    Gazdar AF, Carbone M. Molecular pathogenesis of mesotheliom and its relationship to Simian virus 40. Clin Lung Cancer. 2003;5:177–81.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357:444–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005;104:2181–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1468–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of Minichromosome maintenance protein 7 (MCM7), topoisomerase IIα, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22:4344–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8. 8A.L.PubMedCrossRefGoogle Scholar
  12. 12.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, Reddel RR, Zaffaroni N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2008;14:4134–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453–66.PubMedPubMedCentralGoogle Scholar
  15. 15.
    De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Dera M, Balsari A, Zaffaroni N. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med. 2016;14:25.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer. 2010;46:2837–48.PubMedCrossRefGoogle Scholar
  17. 17.
    Churg A, Roggli VL, Galateau-Salle F, et al. Tumours of the pleura: Mesothelial tumours. In: Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
  18. 18.
    Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142:89–108.CrossRefGoogle Scholar
  19. 19.
    Battifora H, McCaughey WTE. Tumours and pseudotumours of the serosal membranes. In: Atlas of tumour pathology 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 15–88.Google Scholar
  20. 20.
    Roggli VL, Cagle PT. Pleura, pericardium and peritoneum. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, editors. Silverberg’s principles and practice of surgical pathology. 4th ed. New York: Churchill-Livingstone/Elsevier; 2006. p. 1005–39.Google Scholar
  21. 21.
    Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403–18.PubMedCrossRefGoogle Scholar
  22. 22.
    Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25:1304–9.CrossRefGoogle Scholar
  24. 24.
    Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14:2790–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Churg A, Colby TV, Cagle P. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183–200.CrossRefGoogle Scholar
  26. 26.
    Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231–8.CrossRefGoogle Scholar
  27. 27.
    Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407–14.PubMedGoogle Scholar
  28. 28.
    Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.PubMedGoogle Scholar
  29. 29.
    de Pangher V, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348–53.CrossRefGoogle Scholar
  30. 30.
    Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol. 2018;44:792–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. Am J Roentgenol. 2008;191:814–25.CrossRefGoogle Scholar
  33. 33.
    Whitley N, Brenner D, Antman K, Grant D, Aisner J. CT of peritoneal mesothelioma: analysis of eight cases. Am J Roentgenol. 1982;138:531–5.CrossRefGoogle Scholar
  34. 34.
    Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH. Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori. 2005;91:394–400.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–49.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Dubreuil J, Giammarile F, Rousset P, et al. The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. Nucl Med Commun. 2017;38:312–8.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23:187–90.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Rogoff EE, Hilaris B, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer. 1973;32:656–64.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Jones DEC, Silver D. Peritoneal mesothelioma. Surgery. 1979;86:556–60.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982;96:746–55.PubMedCrossRefGoogle Scholar
  41. 41.
    Antman KH, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977–81.PubMedCrossRefGoogle Scholar
  42. 42.
    Kirmani S, Cleary SM, Mowry J, et al. Intracavitary cisplatin for malignant mesothelioma: an update. In: Proc Am Clin Oncol, vol. 7, 1988. (Abstract 1057).Google Scholar
  43. 43.
    van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion. 1989;43:222–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma-incidence and aetiology. Pathologe. 1999;20:169–76.PubMedCrossRefGoogle Scholar
  46. 46.
    Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147–53.PubMedCrossRefGoogle Scholar
  49. 49.
    Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and Leukemia group B. J Clin Oncol. 1993;11:1559–65.PubMedCrossRefGoogle Scholar
  50. 50.
    Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma - results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.PubMedCrossRefGoogle Scholar
  54. 54.
    Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31:49–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2009;16:463–72.PubMedCrossRefGoogle Scholar
  56. 56.
    Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.PubMedCrossRefGoogle Scholar
  57. 57.
    Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69–79.PubMedCrossRefGoogle Scholar
  58. 58.
    Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.Google Scholar
  59. 59.
    Baratti D, Kusamura S, Guaglio M, Deraco M. Peritoneal metastases: challenges for the surgeon. Minerva Chir. 2015;70:195–215.PubMedGoogle Scholar
  60. 60.
    Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416–24.PubMedCrossRefGoogle Scholar
  61. 61.
    Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Bijelic L, Stuart OA, Sugarbaker PH. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012:1–6. Article ID 890450.Google Scholar
  63. 63.
    Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:1720–7.CrossRefGoogle Scholar
  64. 64.
    Robella M, Vaira M, Mellano A, et al. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir. 2014;69:9–15.PubMedGoogle Scholar
  65. 65.
    Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Gilani SNS, Mehta A, Garcia-Fadrique A, et al. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperth. 2018;34:578–84.CrossRefGoogle Scholar
  68. 68.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma—a multi-institutional registry study. J Clin Oncol. 2009;27:6237–42.PubMedCrossRefGoogle Scholar
  69. 69.
    Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–86.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013;20:3892–8.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159–65.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22:1680–5.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma Hyperthermic Intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol. 2018;25:3271–9.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855–63.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20:555–61.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23:1494–8.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Pillai K, Pourgholami MH, Chua TC, Morris DL. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res. 2013;3:411–23.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the peritoneal surface oncology group international registry. Ann Surg Oncol. 2018;25:667–73.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Krasinskas AM, Borczuk AC, Hartman DJ, et al. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. 2016;68:729–37.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Valmary-Degano S, Colpart P, Villeneuve L, et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur J Surg Oncol. 2017;43:1915–23.PubMedCrossRefGoogle Scholar
  81. 81.
    Huang Y, Alzahrani NA, Liauw W, Morris DL. Effects of sex hormones on survival of peritoneal mesothelioma. World J Surg Oncol. 2015;13:210.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Pillai K, Pourgholami MH, Chua TC, Morris DL. MUC1 has prognostic significance in malignant peritoneal mesothelioma. Int J Biol Markers. 2013;28:303–12.PubMedCrossRefGoogle Scholar
  83. 83.
    Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29:14–24.PubMedCrossRefGoogle Scholar
  84. 84.
    Li YC, Khashab T, Terhune J, et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative Cytoreduction and Hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24:2259–65.PubMedCrossRefGoogle Scholar
  85. 85.
    Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98:60–4.PubMedCrossRefGoogle Scholar
  86. 86.
    Nizri E, Baratti D, Guaglio M, et al. Multicystic mesothelioma: operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. Eur J Surg Oncol. 2018;44:1100–4.PubMedCrossRefGoogle Scholar
  87. 87.
    Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: incorporation of a simple pathological grading into recently proposed TNM classification improbe out come prediction. In: 9th International Congress on peritoneal Surface malignancies. Amsterdam, ND. 9-11 October 2014.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Peritoneal Surface Malignancy Unit, Department of SurgeryFondazione IRCCS Istituto Nazionale dei Tumori Via VenezianMilanItaly
  2. 2.Department of PathologyFondazione IRCCS Istituto Nazionale dei Tumori Via VenezianMilanItaly
  3. 3.Division of Surgery, Department of Surgery ATel-Aviv Sourasky Medical Center and Sackler Faculty of MedicineTel AvivIsrael

Personalised recommendations